OpenAI wants to create medicines with AI: buying a biotech startup is its first step

OpenAI has initiated a strategic move into the pharmaceutical sector by acquiring Orchestra Bio, a biotechnology startup. This acquisition is intended to integrate artificial intelligence into the drug development process, utilizing the startup's platform to organize and track the complex workflows required to bring new medications to market.